NASDAQ:FBLG

FibroBiologics Q2 2025 Earnings Results & Report

FibroBiologics logo
$0.84 -0.06 (-6.72%)
Closing price 04:00 PM Eastern
Extended Trading
$0.83 -0.01 (-1.19%)
As of 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

FibroBiologics missed analyst earnings expectations in its Q2 2025 results, released July 31, 2025. The company reported EPS of -$2.40 versus the -$2.20 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

FibroBiologics EPS Results

Actual EPS
-$2.40
Consensus EPS
-$2.20
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

FibroBiologics' Q4 2026 earnings is estimated for Friday, November 20, 2026, based on past reporting schedules

FibroBiologics Q2 2025 Earnings FAQ

FibroBiologics (NASDAQ:FBLG) reported earnings of -$2.40 per share for Q2 2025, missing the consensus estimate of -$2.20. The report was announced on Thursday, July 31, 2025.

FibroBiologics' next earnings date is estimated for Friday, November 20, 2026. MarketBeat tracks confirmed and estimated earnings dates for FibroBiologics on the company's earnings history page.

FibroBiologics Earnings Headlines

FibroBiologics Inc. (NASDAQ:FBLG) Stock Rated "Reduce" by Wall Street Analysts
Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG) is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. Its research centers on fibroblasts, cells found in connective tissue that can support tissue repair and other biological processes.

The company is developing potential therapies for conditions including multiple sclerosis, degenerative disc disease, wound healing and diabetes. Its programs are investigational, and the company’s approach includes exploring fibroblast cells and related technologies as treatments.

FibroBiologics is based in Houston, Texas. The company was founded by Pete O’Heeron, who serves as its chief executive officer.

View FibroBiologics Profile